DOP2009000295A - Compuestos de bencensulfonamida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 - Google Patents
Compuestos de bencensulfonamida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3Info
- Publication number
- DOP2009000295A DOP2009000295A DO2009000295A DO2009000295A DOP2009000295A DO P2009000295 A DOP2009000295 A DO P2009000295A DO 2009000295 A DO2009000295 A DO 2009000295A DO 2009000295 A DO2009000295 A DO 2009000295A DO P2009000295 A DOP2009000295 A DO P2009000295A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- dopamine
- compounds
- alkyl
- fluorinated
- bencensulfonamide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- -1 C-C2-alkyl Chemical group 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 229960003638 dopamine Drugs 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de formula I R1 se selecciona del grupo que consiste en hidrogeno, Cl-C3 alquilo lineal y C1-C3 alquilo lineal fluorado; R2 es hidrogeno o metilo; R3 se selecciona del grupo que consiste en hidrogeno, halogeno, C -C2-alquilo, C1-C2-alquilo fluorado, C1-C2-alcoxilo Y Cl-C2-alcoxilo fluorado, R4 es C1-C2-alquilo o C1-C2-alquilo fluorado; n es 0, 1 o 2, y las sales fisiologicamente tolerables de estos compuestos y los N-oxidos de estos. La invencion tambien se relaciona con una composicion farmaceutica que comprende al menos un compuesto de formula I y/o al menos una sal de adicion acida fisiologicamente tolerable de este, y ademas, con un metodo para tratar trastornos que responden beneficiosamente a los antagonistas del receptor de dopamina D3 o los agonistas de dopamina D3, donde dicho metodo comprende administrarle una cantidad eficaz de al menos un compuesto o una sal de adicion acida fisiologicamente tolerable de formula I a un sujeto que lo necesita.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07119788 | 2007-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2009000295A true DOP2009000295A (es) | 2010-01-31 |
Family
ID=40280677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2009000295A DOP2009000295A (es) | 2007-10-31 | 2009-12-29 | Compuestos de bencensulfonamida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20100210664A1 (es) |
| EP (1) | EP2203426B9 (es) |
| JP (1) | JP5680416B2 (es) |
| KR (1) | KR20100080500A (es) |
| CN (1) | CN101687802B (es) |
| AT (1) | ATE522505T1 (es) |
| AU (1) | AU2008320875B2 (es) |
| BR (1) | BRPI0812978A2 (es) |
| CA (1) | CA2690976A1 (es) |
| CO (1) | CO6251289A2 (es) |
| CR (1) | CR11188A (es) |
| DO (1) | DOP2009000295A (es) |
| EC (1) | ECSP099832A (es) |
| ES (1) | ES2371308T3 (es) |
| GT (1) | GT200900332A (es) |
| IL (1) | IL202814A (es) |
| MX (1) | MX2009014236A (es) |
| MY (1) | MY153300A (es) |
| NZ (1) | NZ582095A (es) |
| RU (1) | RU2485103C2 (es) |
| TW (1) | TWI469782B (es) |
| UA (1) | UA99628C2 (es) |
| WO (1) | WO2009056600A1 (es) |
| ZA (1) | ZA200909171B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122023004130B1 (pt) * | 2013-06-27 | 2023-12-12 | Pfizer Inc | Compostos heteroaromáticos, composição farmacêutica e uso dos referidos compostos no tratamento de distúrbios mediados ou associados a dopamina d1 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102439D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| US7320979B2 (en) * | 2003-04-14 | 2008-01-22 | Abbott Gmbh & Co. Kg. | N-[(piperazinyl)hetaryl]arylsulfonamide compounds |
| US20040204422A1 (en) * | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
-
2008
- 2008-10-30 AU AU2008320875A patent/AU2008320875B2/en not_active Ceased
- 2008-10-30 UA UAA201003729A patent/UA99628C2/ru unknown
- 2008-10-30 WO PCT/EP2008/064732 patent/WO2009056600A1/en active Application Filing
- 2008-10-30 CA CA2690976A patent/CA2690976A1/en not_active Abandoned
- 2008-10-30 ES ES08844327T patent/ES2371308T3/es active Active
- 2008-10-30 BR BRPI0812978-9A2A patent/BRPI0812978A2/pt not_active IP Right Cessation
- 2008-10-30 JP JP2010530492A patent/JP5680416B2/ja not_active Expired - Fee Related
- 2008-10-30 EP EP08844327A patent/EP2203426B9/en active Active
- 2008-10-30 US US12/666,627 patent/US20100210664A1/en not_active Abandoned
- 2008-10-30 RU RU2010121830/04A patent/RU2485103C2/ru not_active IP Right Cessation
- 2008-10-30 MX MX2009014236A patent/MX2009014236A/es active IP Right Grant
- 2008-10-30 NZ NZ582095A patent/NZ582095A/xx not_active IP Right Cessation
- 2008-10-30 AT AT08844327T patent/ATE522505T1/de not_active IP Right Cessation
- 2008-10-30 MY MYPI20095655A patent/MY153300A/en unknown
- 2008-10-30 TW TW97141857A patent/TWI469782B/zh not_active IP Right Cessation
- 2008-10-30 KR KR1020097027266A patent/KR20100080500A/ko active IP Right Grant
- 2008-10-30 CN CN200880023090.9A patent/CN101687802B/zh not_active Expired - Fee Related
-
2009
- 2009-12-17 IL IL202814A patent/IL202814A/en not_active IP Right Cessation
- 2009-12-22 ZA ZA2009/09171A patent/ZA200909171B/en unknown
- 2009-12-29 DO DO2009000295A patent/DOP2009000295A/es unknown
- 2009-12-29 EC EC2009009832A patent/ECSP099832A/es unknown
- 2009-12-29 CO CO09148550A patent/CO6251289A2/es not_active Application Discontinuation
- 2009-12-29 GT GT200900332A patent/GT200900332A/es unknown
-
2010
- 2010-01-04 CR CR11188A patent/CR11188A/es unknown
-
2011
- 2011-07-21 US US13/187,885 patent/US20110319421A1/en not_active Abandoned
-
2013
- 2013-12-04 US US14/096,565 patent/US20140200224A1/en not_active Abandoned
-
2014
- 2014-11-25 US US14/553,923 patent/US20150175570A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072224A1 (es) | Derivados de pirimidona sustituidos | |
| PE20142294A1 (es) | Compuestos de indol e indazol que activan la ampk | |
| EA200900606A1 (ru) | Новые сульфониламидные производные в качестве антагонистов брадикининовых рецепторов | |
| CO6311070A2 (es) | Compuestos triazina como inhibidores mtor y quinasa pi3 | |
| UY31050A1 (es) | Antagonistas de trpv1 y usos de los mismos | |
| AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
| UY32848A (es) | Compuestos heterocíclicos de oxima | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR056762A1 (es) | (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| ECSP066536A (es) | Derivados de acidos fenoxiaceticos utiles como agonistas dobles dereceptor activado por proliferador de peroxisoma | |
| EA200900605A1 (ru) | Новые производные фенилсульфамоил бензамидов в качестве антагонистов брадикининовых рецепторов | |
| AR054341A1 (es) | Combinaciones sinergicas de compuestos activos fungicidas | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| PE20091182A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-CARBOXAMIDAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| EA200901474A1 (ru) | Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе | |
| PE20091450A1 (es) | INHIBIDORES DE LA ESTEAROIL-CoA-DESATURASA | |
| PE20080949A1 (es) | Azolilmetiloxiranos, su uso para combatir hongos fitopatogenos, asi como productos que los contienen | |
| UY31824A (es) | Nuevos compuestos | |
| DOP2010000126A (es) | Compuestos de 1,2,4-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3 | |
| PE20081495A1 (es) | Derivados 4,5-difenilpirrol-2-carboxamida como antagonistas de los receptores cb1 | |
| DOP2009000295A (es) | Compuestos de bencensulfonamida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 | |
| CR11860A (es) | Derivados de dibenzotiazepina y sus usos - 424 | |
| AR072103A1 (es) | Derivados de (piperazinilo con enlaces puente)-1- alcanona, su utilizacion como inhibidores de p75 y composiciones farmaceuticas que los contienen | |
| AR070020A1 (es) | Uso de antagonistas de mglur5 para el tratamiento de la gerd, composicion farmaceutica y metodo de tratamiento |